Kelli Rhodes
Psychiatric/Mental Health · Lagrange, INNPI 1801402128
Payments from drug & device makers
Across 262 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$875
- Teva Pharmaceuticals USA, Inc.$444
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$399
- Supernus Pharmaceuticals, Inc.$390
- Alkermes, Inc.$371
- Otsuka America Pharmaceutical, Inc.$351
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,11096%
- Education$1924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $875 |
| Teva Pharmaceuticals USA, Inc. | 22 | $444 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $399 |
| Supernus Pharmaceuticals, Inc. | 27 | $390 |
| Alkermes, Inc. | 21 | $371 |
| Otsuka America Pharmaceutical, Inc. | 10 | $351 |
| Sunovion Pharmaceuticals Inc. | 19 | $330 |
| E.r. Squibb & Sons, L.L.C. | 13 | $272 |
| Lundbeck LLC | 19 | $253 |
| Idorsia Pharmaceuticals US Inc | 6 | $200 |
| Axsome Therapeutics, Inc. | 6 | $108 |
| Corium, LLC | 4 | $79 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Biogen | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $19 |
| Tris Pharma Inc | 1 | $16 |
| Braeburn Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
- COBENFY$123
- QUVIVIQ$121
- ABILIFY MAINTENA$117
How this compares
$4,302 in reported general payments places this provider in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $157,488 |
| Invega SustennaPaliperidone Palmitate | 13 | $48,026 |
| CaplytaLumateperone Tosylate | 26 | $41,543 |
| VraylarCariprazine Hcl | 22 | $40,535 |
| UzedyRisperidone | 13 | $34,399 |
| Abilify MaintenaAripiprazole | 11 | $25,827 |
| TrintellixVortioxetine Hydrobromide | 26 | $19,497 |
| Aripiprazole | 82 | $6,262 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,079 |
| Duloxetine Hcl | 78 | $1,497 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,388 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $1,165 |
| Haloperidol Decanoate | 15 | $1,138 |
| Sertraline Hcl | 97 | $816 |
| Fluoxetine Hcl | 45 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $56 | $157,48819 claims |
| Johnson & JohnsonInvega Sustenna | $21 | $48,02613 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $399 | $41,54326 claims |
| AbbVieVraylar | $875 | $40,53522 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $444 | $34,39913 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $351 | $25,82711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $49 | $23,57638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Lagrange
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.